Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical chemotherapy for UTUC recurrence prevention
NCT05810623Phase 3Not yet recruiting
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in bladder cancer (2 arms). Primary endpoint: Efficacy of a single immediate intravesical chemotherapy instillation in the prophylaxis of intravesical recurrence at 2 years. Planned start Jun 2023; status: not yet recruiting.
02
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05810623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810623.